Boulder, Colorado - Jun 12, 2015 - Bolder BioTechnology, Inc. announced today that it has been awarded the third year of a five year U01 Cooperative Research Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant is a joint research project between Bolder BioTechnology and Indiana University School of Medicine (Indianapolis, IN). George Cox, Ph.D. of Bolder BioTechnology, Inc. and Christie Orschell, Ph.D. of Indiana University School of Medicine are co-Principal Investigators for the grant. Receipt of the entire grant award is contingent upon the continued achievement of certain research milestones.
George (Joe) Cox, Ph.D., Company President said, “We are delighted to receive continued research funding from NIAID to determine how three of the long-acting hematopoietic (blood cell) growth factors we are developing are able to prevent death of lethally irradiated mice, even when the proteins are not administered until 24 hours following radiation exposure. Development of drugs to prevent death and treat complications of radiation exposure is a high priority research area for NIAID due to the increasing threat of a terrorist nuclear attack. One of the first clinical signs of high dose radiation exposure is death of hematopoietic stem cells, which leads to severe reductions in white blood cells and platelets within a few weeks. Low numbers of white blood cells and platelets leaves patients susceptible to infections and uncontrolled bleeding, and often results in death. Research results obtained by Dr. Orschell’s laboratory during the past year confirmed the ability of our three blood cell growth factors to significantly improve survival of lethally irradiated mice, and determined that even greater survival rates could be obtained by administering mice combinations of the three proteins. Improved survival due to treatment with of the protein combinations was most evident at high radiation doses. Dr. Orschell’s group also found that mice treated with the protein combinations possessed higher numbers of hematopoietic stem and progenitor cells than non-treated mice following radiation exposure, which may contribute to the ability of the protein combinations to increase survival.”
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. Research described herein has been supported by grants AI107340, AI084288, AI084301, and AI088298 from NIH.
Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company’s ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company’s ability to obtain required government approvals; (3) the Company’s ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company’s ability to develop and commercialize its products before its competitors.
Contact information:
Joe Cox, Ph.D., President (303)-420-4420 x-202 www.bolderbio.com
